IRVINE, Calif, March 23, 2006 (PRIMEZONE) -- "Despite the fact that embryonic stem cells and the wave of controversy surrounding their use has dominated the stem cell spotlight, adult stem cell treatments are gaining attention in the medical community," stated SmallCap Sentinel analyst D.R. Clark.
Adult stem cells are found in human tissue and organs. While not as versatile as embryonic stem cells, they have been studied in much greater depths, appear to be safer and can become a multitude of different tissue types such as heart muscle, tendons, cartilage, nerve, bones and liver tissue.
"Recent news headlines note the use of adult stem cells in the treatment of heart failure, cartilage disease, and immune disorders," stated Clark. "And unlike the embryonic stem cell lines, little controversy seems to follow the adult stem cell research and treatments."
Medistem Laboratories (OTCBB:MDSM) portfolio of biotechnology looks to capitalize on the enormous human potential of stem cell research while shedding the ethical constraints of other stem cell research fields. The company's science is derived from what it terms non-controversial sources.
The informational report "Looking at the Political Impact on Stem Cell Research" is available at www.SmallCapSentinel.com and will address issues affecting stem cell companies including Medistem Laboratories Inc. (OTCBB:MDSM), Stemcells Inc. (Nasdaq:STEM), Aastrom Biosciences Inc. (Nasdaq:ASTM), and Geron Corp. (Nasdaq:GERN).
Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities.
A detailed informational report regarding Medistem is available free to the public at the following link: http://trilogy-capital.com/mdsm_summary.aspx
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Medistem for preparation and distribution of this report and other advertising services. An editor of SmallCap Sentinel currently holds a position in STEM. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.